A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma

Table 5 The most common (≥ 10%) TEAEs in the safety analysis set

	Ixazomib + LenDex N = 34 n (%)
Patients with at least 1 AE	34 (100)
Constipation	17 (50)
Upper respiratory tract infection	16 (47)
Diarrhea	14 (41)
Rash	12 (35)
Nasopharyngitis	11 (32)
Nausea	10 (29)
Platelet count decreased	9 (26)
Influenza	8 (24)
Neutropenia	8 (24)
Chilblains	7 (21)
Dysgeusia	7 (21)
Fall	7 (21)
Peripheral sensory neuropathy	7 (21)
Bronchitis	6 (18)
Neutrophil count decreased	6 (18)
Dental caries	5 (15)
Malaise	5 (15)
Edema peripheral	5 (15)
Pharyngitis	5 (15)
Maculopapular rash	5 (15)
Vomiting	5 (15)
Back pain	4 (12)
Dry skin	4 (12)
Hyperglycemia	4 (12)
Oropharyngeal pain	4 (12)
Pain in extremity	4 (12)
Pneumonia	4 (12)
Pyrexia	4 (12)
Stomatitis	4 (12)
Thrombocytopenia	4 (12)
Urticaria	4 (12)

AE adverse event, LenDex lenalidomide and dexamethasone, TEAE treatment-emergent adverse event